Thomas McCauley, PhD, on Continuing Evaluations on OTX-2002 for MYC-Expressing Cancers


The chief scientific officer at Omega Therapeutics discussed milestones Omega Therapeutics is looking forward to in the next year.

This is the fourth part of an interview with Thomas McCauley, PhD. For the third part, click here.

“We're going to trial in the United States, Asia and Europe. Asia is critical here in the sense that, in the US, hepatocellular carcinoma (HCC) is a more rare condition. But globally, and particularly in Asia, HCC is really very prevalent. So, there's a lot of lot of unmet need there in the second line, and even in first line treatment, depending on the region.”

OTX-2002, a MYC-targeted Omega Epigenomic Controller (OEC) therapy developed by Omega Therapeutics, has demonstrated specific, on-target genomic engagement and proof-of-concept in changing the epigenetic state and downregulating expression of c-MYC in patients with hepatocellular carcinoma (HCC) and other solid tumors associated with the c-MYC (MYC) gene in preliminary data from the phase 1/2 MYCHELANGELO-1 trial (NCT05497453).

MYCHELANGELO-1 has treated 4 patients in each of 2 dose level cohorts, receiving either 0.02 mg/kg or 0.05 mg/kg of OTX-2002 monotherapy intravenously every 2 weeks. The second part of the study will assess OTX-2002 in combination therapy. The therapy was well tolerated with no dose-limiting toxicities (DLTs) and the maximum tolerated dose was not reached. Most adverse events (AEs) were grade 1 or 2 (87%) and the most common treatment-related AEs were infusion-related reactions (26%.

CGTLive spoke with Thomas McCauley, PhD, chief scientific officer, Omega Therapeutics, to learn more about OTX-2002. He also discussed milestones Omega is looking forward to in the next year.

McCauley T. MYCHELANGELO™ I preliminary data overview. Presentation. September 26, 2023.
Related Videos
Alfonso Sabater, MD, PhD, on Bringing Gene Therapy to Ophthalmology
Sharon Hesterlee, PhD
Thomas Crawford, MD, on Helping Patients With SMA Left Behind by Gene Therapy
J. Andrew Livingston, MD
Shankar Musunuri, PhD
© 2023 MJH Life Sciences

All rights reserved.